FDA to release guidance on trial-related adverse events

05/11/2008 | FDAnews

The FDA is set to issue a final guidance that differentiates between adverse events and unexpected problems in clinical studies and explains when to report side effects to institutional review boards. The agency will "probably institute regulatory changes" following the guidance's release, a biophysicist with the FDA's Good Clinical Practices Program said during a conference.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ